

Promore Pharma is granted a US patent regarding skin scarring

STOCKHOLM, 12 May 2021 - Promore Pharma AB, a Swedish biopharmaceutical development company focusing on therapeutic peptides, announced today that the company has received a granted patent in the US for the use of the candidate drug ensereptide (PXL01) to prevent the formation of scarring on the skin.

Promore Pharma's product candidate ensereptide is undergoing development for treatments aiming at preventing various forms of scarring. The company made Promore Phar has today been granted a patent in the United States for the use of a pharmaceutical formulation containing the peptide PXL01 and hyaluronic acid, for the prevention of scarring after surgery. The patent period extends at least until 2030, with the possibilities of further patent extension.

"We are now taking another step in our strategic work to create far-reaching intellectual property protection for our innovative prescription drug for the treatment of various types of scars," said Jonas Ekblom, CEO of Promore Pharma. "Overall, we now have strong and extensive patent protection for ensereptide in the world's largest pharmaceutical market, which will be of paramount importance when our product reaches the market," he continued.

The company has recently announced that it intends to begin development of ensereptide to prevent unfavorable scarring on the skin. This is a product area with enormous potential. Every year, more than 300 million surgical procedures are performed worldwide, and in many cases long-lasting or permanent scars occur, for example in plastic and trauma surgery. Today, no pharmaceutical products are available aimed specifically for prevention of skin scarring. The company estimates that the annual addressable market exceeds SEK 100 billion.

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 565 245

E-mail: erik.magnusson@promorepharma.com

Promore Pharms Certified Adviser is Erik Penser Bank

Tel: [+46] 8-463 83 00

E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

About ensereptide (PXL01)

Ensereptide is a derivative of a human antibacterial protein (lactoferrin), which is part of the immune system. This protein and its fragments have several mechanisms of action, including an immunomodulatory effect and an increase in fibrinolytic activity. It is well known that inflammation and fibrin formation are two central mechanisms for causing scarring after trauma and surgery. The development of ensereptide initially focuses on preventing various types of scarring after surgery. In phase II study that was sponsored and conducted by the company in several EU countries, ensereptide showed good effect and safety.

Promore Pharma is preparing a Phase II clinical study in the EU as a step in developing a product to limit scarring on the skin. The study is planned to start in the beginning of 2022.

Every year, more than 300 million surgical procedures are performed worldwide, and a proportion of these procedures results in disfiguring skin scars, for example in plastic- and trauma surgery. Today, there are no pharmaceutical products available for prevention of scars after trauma and surgery. The annual addressable market is estimated to exceed SEK 100 billion. In other types of surgical procedures, there is a risk of the occurrence of internal scars, which can cause adverse adhesions (undesirable attachments between tissue surfances). This is a major medical problem, for example in hand surgery in connection with injuries to tendons in the hand.

Attachments

[Promore Pharma is granted a US patent regarding skin scarring](#)